We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-13.07%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$305M
AUM Growth
-$79.2M
Cap. Flow
-$9.26M
Cap. Flow %
-3.04%
Top 10 Hldgs %
82.61%
Holding
19
New
–
Increased
2
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$755K
2
REPL icon
Replimune Group
REPL
+$434K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$6.99M
2
AKAO
Achaogen Inc
AKAO
+$1.31M
3
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$815K
4
WVE icon
Wave Life Sciences
WVE
+$701K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$627K

Sector Composition

Rank Sector Weight
1 Healthcare 67.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$57.6M 18.9%
1,950,477
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$44.1M 14.47%
467,682
– –
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$34.6M 11.36%
2,942,130
– –
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$26.9M 8.82%
1,938,612
-464,786
-19% -$6.99M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.4B
$23.5M 7.71%
204,088
– –
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.8M 5.17%
314,400
– –
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$13.5M 4.42%
647,254
– –
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$12.5M 4.11%
998,278
– –
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.9M 3.92%
315,331
– –
REPL icon
10
Replimune Group
REPL
$434M
$11.4M 3.75%
779,656
+30,002
+4% +$434K
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$11.4M 3.73%
1,587,101
– –
RCUS icon
12
Arcus Biosciences
RCUS
$3.38B
$10.9M 3.56%
1,366,973
– –
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$10.5M 3.43%
254,923
– –
NTRA icon
14
Natera
NTRA
$36.3B
$7.9M 2.59%
286,468
+34,213
+14% +$755K
FBRX icon
15
Forte Biosciences
FBRX
$1.57B
$3.79M 1.24%
1,515
– –
WVE icon
16
Wave Life Sciences
WVE
$1.13B
$3.65M 1.2%
139,900
-25,000
-15% -$701K
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.86M 0.94%
65,249
-11,130
-15% -$627K
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.11M 0.69%
454,656
-175,000
-28% -$815K
AKAO
19
DELISTED
Achaogen Inc
AKAO
– –
-2,864,664
Closed -$1.31M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2019 Portfolio in Review

As of Q2 2019, Foresite Capital Management III held 19 positions worth $305M, down 21% from $384M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Foresite Capital Management III withdrew a net $9.26M in Q2 2019, closing 1 position and reducing 4 holdings. Its most notable exit was Achaogen Inc, an estimated $1.31M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 60% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $755K to Natera.

  • Foresite Capital Management III added most to Natera in Q2 2019, an estimated $755K increase.
  • Foresite Capital Management III's biggest Q2 2019 reduction was Immunomedics Inc, cutting an estimated $6.99M.
  • Foresite Capital Management III fully exited Achaogen Inc in Q2 2019, selling an estimated $1.31M.
  • Foresite Capital Management III's ten largest holdings make up 83% of its $305M portfolio in Q2 2019.
  • Foresite Capital Management III opened 0 new positions and closed 1 in Q2 2019.
  • Foresite Capital Management III's portfolio value fell 21% quarter-over-quarter to $305M.

Based on Foresite Capital Management III's 13F filing for Q2 2019, filed 13 Aug 2019.